FACT-CHECK
Why Seegene and Alteogen Stocks Fell 17%+ as KOSDAQ Slipped 0.8%
Seegene fell 20.81% after its Q3 earnings disclosure. Alteogen fell 16.81% on reports of U.S. drug price pressure, with no company filing.
1 article(s) on Korean Diagnostics stocks, checked against filings and numbers.
Seegene fell 20.81% after its Q3 earnings disclosure. Alteogen fell 16.81% on reports of U.S. drug price pressure, with no company filing.